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Abstract
Background: Matrix metalloproteinases (MMPs) are crucially involved in the regulation of multiple stages of cancer
progression. Elevated MMP levels have been associated with the development of metastases and poor prognosis in
several types of cancer. However, the role of MMPs in osteosarcoma and their prognostic value is still unclear.
Available data are conflicting, most likely due to different technical approaches. We hypothesized that in contrast to
total mRNA or protein levels frequently analyzed in previous studies the enzymatic activities of MMPs and their
inhibitors the tissue inhibitors of matrix metalloproteinases (TIMPs) are closer related to their biological functions.
We therefore aimed to evaluate the reliability of different zymography techniques for the quantification of MMP
and TIMP activities in osteosarcoma biopsies in order to investigate their distribution, possible regulation and
prognostic value.
Methods: All analyses were done using cryo-conserved osteosarcoma pretreatment biopsies (n = 18). Gene and
protein expression of MMPs and TIMPs were analyzed by RT-qPCR and western blot analysis, respectively. Overall
MMP activity was analyzed by in situ zymography, individual MMP activities were analyzed by gelatin zymography.
Reverse zymography was used to detect and quantify TIMP activities.
Results: Strong overall MMP activities could be detected in osteosarcoma pretreatment biopsies with MMP2 and
MMP9 as predominant active MMPs. In contrast to total RNA or protein expression MMP2 and MMP9 activities
showed significant quantitative differences between good and poor responders. While MMP9 activity was high in
the good responder group and significantly decreased in the poor responder group, MMP2 activity showed a
reverse distribution. Likewise, significant differences were detected concerning the activity of TIMPs resulting in a
negative correlation of TIMP1 activity with MMP2 activity (p = 0.044) and negative correlations of TIMP2 and TIMP3
with MMP9 activity (p = 0.007 and p = 0.006).
Conclusion: In contrast to mRNA or protein levels MMP and TIMP activities showed significant differences between
the analyzed good and poor responder groups. A shift from MMP9 to predominant MMP2 activity is associated
with poor response to chemotherapy suggesting that the ratio of MMP2/MMP9 activity might be a valuable and
easily accessible marker to predict the response to chemotherapy in osteosarcoma.
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Background
Osteosarcoma is the most common primary tumor of
the bone, typically affecting the long tubular bones of
children and adolescents. The introduction of effective
neoadjuvant and adjuvant chemotherapy significantly
improved outcome with long-term relapse free survival
rates ranging from 55 to 75 % over the last several
decades [1, 2]. However, the remainder of patients
will relapse, most often with pulmonary metastases
and poor response to chemotherapy [3]. Therefore,
stratification of patients at time of diagnosis into low
and high risk groups is highly warranted to improve
outcome of high-risk patients and minimize toxicity
of therapy for low-risk patients by means of a risk-adapted
therapy. Histologic response of the tumor to chemother-
apy is still the most reliable prognostic factor, but cannot
be assessed at the time of diagnosis.
Matrix metalloproteinases (MMPs) are proteolytic en-
zymes that play a major role in extracellular matrix
(ECM) remodeling but have also been shown to be
involved in the regulation of multiple stages of cancer
progression including cell growth, differentiation, apop-
tosis, migration, invasion and immune surveillance [4, 5].
Elevated MMP levels have been shown to be associated
with metastasis and poor prognosis in several types of
cancer [6, 7]. MMPs further play an important role in
the regulation of angiogenesis. Besides the degradation of
the ECM that promotes the detachment and migration of
endothelial cells, MMPs contribute to the release of
proangiogenic factors like bFGF, VEGF and TGF-ß from
the ECM [8].
Regulation of MMP activity is a complex process that
occurs at multiple levels including gene expression, pro-
teolytic activation of the latent pro-forms of the enzymes
and interaction with their physiological inhibitors, the
tissue inhibitors of matrix metalloproteinases (TIMPs)
[9]. The TIMP family consists of four members (TIMP-
1, −2, −3, −4) that are, besides inhibition of MMP activ-
ity, involved in several cellular processes including inhib-
ition of apoptosis and activation of cell survival
pathways [10]. The role of MMPs and TIMPs in osteo-
sarcoma and their prognostic value is still unclear and
available data are conflicting. Most studies so far focused
on the analysis of gene and protein expression while data
on enzyme activity are very limited. In addition, the
prognostic value of MMPs has been evaluated mainly
concerning overall and event-free survival. Associations
of MMPs with response to chemotherapy have not been
studied yet.
Therefore, the aim of our study was to evaluate the re-
liability of different zymography techniques for the
quantification of MMP and TIMP activities in order to
investigate their distribution in osteosarcoma tissue and
to reveal possible prognostic properties.
Methods
Patients and treatment
All patients included in our study were diagnosed for
osteosarcoma by open tumor biopsy between 2005 and
2012 and received equal neoadjuvant chemotherapy ac-
cording to the standard recommendations within the
EURAMOS-1 (European and American osteosarcoma
study group) treatment study. The neoadjuvant treat-
ment is based on high dose Methotrexate, Doxorubicin
and Cisplatin. Following tumor resection patients are
stratified for further adjuvant chemotherapy according
to their response to neoadjuvant chemotherapy.
Our study design, investigating enzyme activity of
MMPs and TIMPs, demanded fresh frozen tumor tissue
of adequate quality. Out of 37 treatment naive fresh fro-
zen osteosarcoma samples collected between 2005 and
2012 in our bone tumor tissue bank, sufficient clinical
data were available for 31 cases. In four cases, the quan-
tity of the preserved tumor tissue was not sufficient for
further investigations, and nine fresh frozen tumor sam-
ples demonstrated significant signs of degradation of
RNA and proteins. Therefore 18 samples remained avail-
able for further investigations. Response to preoperative
chemotherapy was assessed histologically by the patholo-
gist according to the six-grade scale of Salzer-Kuntschik
[11] where grade 1 denotes no viable tumor cells; grade
2; solitary viable cells or one islet of less than 0.5 cm;
grade 3; less than 10 %; grade 4; 10 % to 50 %; grade 5;
more than 50 % and grade 6; no effect of chemotherapy.
In this classification a good response is defined as less
than 10 % viable tumor cells corresponding to response
grades 1 through 3. Reflecting approximately the distri-
bution of poor and good responders observed in larger
studies [12], nine good and nine poor responders were
identified within our included patients.
RNA extraction
For quantitative RT-PCR analyses total RNA was ex-
tracted from cryoconserved tumor samples. Frozen tis-
sue was pulverized in a Micro-Dismembrator-S (Braun,
Melsungen, Germany) and resuspended in RNA lysis
buffer included in the mirVana RNA isolation kit (Invi-
trogen, Darmstadt, Germany). All further steps were per-
formed according to manufacturer protocol. RNA purity
and concentration were determined with a NanoDrop
ND-100 spectrometer (PeqLAb, Erlangen, Germany).
cDNA synthesis and quantitative RT-PCR
First strand complementary DNA (cDNA) was synthe-
sized from 1 μg of total RNA using 1 μl Omniscript
(Qiagen, Hilden, Germany), 10 μM oligo-dT primer,
5 mM dNTPs and 10U RNaseOut (Invitrogen, Karlsruhe,
Germany) for 2 h at 37 °C in a total volume of 20 μl.
Quantitative real-time PCR was performed in the real-
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time thermal cycler Mx3005p (Agilent Technologies,
Waldbronn, Germany) in a total volume of 20 μl using
Absolute QPCR SYBR Green mix (Thermo scientific,
Dreieich, Germany) and 1 μl of cDNA as template. Samples
were heated to 95 °C for 15 min followed by 40 cycles of
denaturation at 95 °C for 15 s, annealing at 58 °C for 20 s
and extension at 72 °C for 30 s. After the last cycle, a melt-
ing curve analysis was performed to verify the specificity of
the amplified PCR products. Calculated gene expression
was normalized on the basis of the expression of RPL19
(ribosomal protein L19) in the corresponding sample. The
following primers were used: TIMP1-F: 5′-GGGCTTCAC
CAAGACCTACA-3′, TIMP1-R: 5′-TGCAGGGGATGGA
TAAACAG-3′, TIMP2-F: 5′-GAAGAGCCTGAACCAC
AGGT-3′, TIMP2-R: 5′-CGGGGAGGAGATGTAGCAC-
3′, TIMP3-F: 5′-GTGCAACTTCGTGGAGAGGT-3′, TI
MP3-R: 5′-AGCAGGACTTGATCTTGCAGT-3′, MMP2-
F: 5′-ATAACCTGGATGCCGTCGT-3′, MMP2-R: 5′-AG
GCACCCTTGAAGAAGTAGC-3′, MMP9-F: 5′-GAACC
AATCTCACCGACAGG-3′, MMP9-R: 5′-GCCACCCGA
GTGTAACCATA-3′,, RPL19-F: 5′-GTGGCAAGAAGAA
GGTCTGG-3′, RPL19-R: 5′-GCCCATCTTTGATGAGC
TTC-3′
Protein extraction
For isolation of total proteins from osteosarcoma biop-
sies, cryo-conserved tissue was pulverized in a Micro-
Dismembrator-S (Braun) and resuspended in RIPA lysis
buffer (Santa Cruz, Heidelberg, Germany) without the
addition of protease inhibitors. Lysates were further
homogenized two times by sonication for 30 s on ice.
Lysates were incubated at 4 °C for 1 h and centrifuged
at 12000 g for 10 min to remove cellular debris. Super-
natants were recovered and protein concentrations
were determined by BCA assay (Fisher Scientific,
Schwerte, Germany).
Western blot
For the detection of TIMP and MMP protein expression
15 μg of total protein was separated on a 10 % polyacryl-
amide gel and transferred to Immobilon-P membranes
(Millipore, Schwalbach, Germany). After blocking in
PBS supplemented with 5 % skim milk (Sigma-Aldrich)
and 0.05 % Tween 20 (Sigma-Aldrich) membranes were
incubated overnight at 4 °C with one of the following
primary antibodies at the indicated dilutions: MMP2
(1:500) (Abcam, Cambridge, United Kingdom), MMP9
(1:500) (Abcam) TIMP1 (1:250) (Abcam), TIMP2 (1:250)
(Abcam), TIMP3 (1:250) (Abcam). After washing three
times in PBS containing 0.1 % Tween 20 membranes
were incubated for 1 h at room temperature with 5000-
fold diluted peroxidase conjugated goat anti-mouse IgG
(Santa Cruz). Proteins recognized by the antibody were
visualized with luminata forte western blotting substrate
(Millipore) according to the manufacturer’s instructions.
Signal intensities were quantified by densitometry
using Bio-1D software version 15.01 (Vilber Lourmat,
Eberhardzell, Germany).
Gelatin zymography and reverse zymography
For the analysis of MMP activities in osteosarcoma tissue,
equal amounts of total proteins (10 μg) were separated
without heating of the samples and without addition of ß-
mercaptoethanol on a 10 % SDS-polyacrylamid gel includ-
ing 0.15 % gelatin (Sigma-Aldrich, München, Germany).
As positive control culture supernatant from MG63 osteo-
sarcoma cells was used. As negative control RIPA lysis
buffer was loaded on the gel. Gels were washed two times
in 2.5 % Triton-X 100 for 20 min and incubated for 16 h
at 37 °C in developing buffer consisting of 150 mM NaCl,
5 mM CaCl2 and 50 mM Tris pH8.0 (Carl-Roth, Karls-
ruhe, Germany). After staining with 0.5 mg/ml Coomassie
Brilliant Blue R-250 (Sigma) in 10 % acetic acid and 25 %
methanol for 2 h with gentle agitation, gels were destained
for further 2 h in 8 % acetic acid and 4 % methanol
and photographed. Signal intensities were quantified
by densitometry using Bio-1D software version 15.01
(Vilber Lourmat, Eberhardzell, Germany).
Reverse zymography was performed as described
above, except that the polyacrylamide gels were supple-
mented with culture supernatant from osteosarcoma
MG63 cells containing MMP2. The culture supernatant
was concentrated 6-fold by Centriplus YM-3 centrifugal fil-
ter devices before 500 μl was added to 7.5 ml gel. Incuba-
tion, staining and destaining was performed as described
for gelatin zymography. As positive control 100 ng recom-
binant TIMP1 and 100 ng TIMP2 (PeproTech, Hamburg,
Germany) were combined and loaded on the gel. As nega-
tive control RIPA lysis buffer was used.
In situ zymography
In situ zymography was performed on 10 μm cryosections
of osteosarcoma pretreatment biopsies. Sections were
thawed, and equilibrated for 10 min at 20 °C in incubation
buffer consisting of 50 mM Tris pH 7.4, 150 mM NaCl
and 5 mM CaCl2. Sections were then covered with 100 μl
of incubation buffer supplemented with (50 μg/ml) FITC
conjugated DQ gelatin as substrate (Life Technologies,
Darmstadt, Germany). After incubation for 16 h at 37C in
a wet chamber sections were washed 3 times for 5 min in
TBS buffer and mounted using Roti-Mount FluorCare
(Carl-Roth) containing DAPI as nuclear counterstain. For
negative controls CaCl2 in the incubation buffer was re-
placed by 10 mM EDTA.
Statistics
Statistical analysis was done using SPSS 22 software.
Statistical comparison of experimental groups was done
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using a Mann-Whitney-U test. Calculation of corre-
leation coefficients of MMP and TIMP activities was
done using a Pearson correlation analysis. Results
were defined as significant if p < 0.05 and highly sig-
nificant if p < 0.01.
Results
Total MMP activity was analyzed by in situ zymography
on cryosections derived from osteosarcoma pretreatment
biopsies. As substrate, a highly quenched FITC labeled
gelatin was used that does not produce any fluorescence
in the absence of MMP activity. Upon MMP induced
proteolytic digestion a bright, green fluorescence is re-
vealed suitable for densitometric quantification of total
enzyme activity. Using this technique we observed a
strong total MMP activity in all analyzed samples. The
majority of MMP activity was located on the cell surface
and less activity was found in the ECM. Densitometric
quantification of the MMP positive area within the tissue
sections did not detect any significant differences be-
tween the good (11.4 %) and poor responder group
(12.5 %) (Fig. 1). To identify individual differences we
next analyzed RNA and protein expression of MMP2,
MMP9, TIMP1, TIMP2 and TIMP3 by RT-qPCR and
western-blot analysis. Expression of all genes could be
detected in the analyzed samples. However, although all
genes showed a trend to be downregulated in the poor
responder group we could not detect any significant dif-
ferences between the analyzed groups (Fig. 2a).
Likewise, protein expression could be detected in all
samples but densitometric quantification of the protein
bands did not detect any significant differences between
the analyzed groups (Fig. 2 b + c).
To verify our hypothesis that the analysis of MMP and
TIMP activities is more informative concerning clinical
parameters than total RNA or protein levels we next an-
alyzed MMPs and TIMPs in protein lysates by zymogra-
phy. Based on the different size of the proteins we could
detect the pro- and active forms of MMP2 and MMP9
in all analyzed samples. The activities of both MMPs
showed significant quantitative differences between the
good and poor responder group. While MMP9 activity
was high in the good responder group and low in the
poor responder group, MMP2 activity showed a reverse
distribution (Fig. 3a). Quantitative analysis of the detected
MMP activities by densitometry confirmed these observa-
tions. While the amount of active MMP2 increased 3.2-
fold in the poor responder group, the amount of active
MMP9 decreased 7.6-fold in this group. Comparable
changes were observed for the total activities of MMP2
and MMP9 as well as the latent pro-forms of these en-
zymes that are activated during zymography by SDS-
mediated denaturation and subsequent renaturation of the
zymogens (Fig. 3b). As a consequence, the mean ratio of
total-, active- and pro-MMP2/MMP9 activity significantly
increased 23-fold (p = 0.00059), 59-fold (p = 0.0378)
and 33-fold (p = 0.00026), respectively in the poor re-
sponder group. (Fig. 3c). Using the calculated medians
of the MMP ratios as cutoff value a correct prediction of
chemotherapy response would have been possible in 100 %
(total-MMPs), 100 % (pro-MMPs) and 89 % (active-
MMPs) of cases. To analyze, whether modulated TIMP
Fig. 1 Analysis of total MMP activity in osteosarcoma biopsies by in situ zymography. Green fluorescent areas represent MMP mediated degradation
of FITC-labeled substrate. Representative in situ zymographies of cryosections derived from (a) good responder and (b) poor responder are shown.
Yellow frames indicate the area of magnification shown in (c) and (d). DAPI counterstain of nuclei is shown in blue
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activities may be responsible for the observed differences
in MMP activities we performed reverse zymography with
the same samples. In this assay, MMPs derived from
culture supernatants of an osteosarcoma cell line were
incorporated together with gelatin into the polyacryl-
amide gel. TIMPs within the analyzed protein lysates
inhibited the MMP induced gelatin degradation and
could thus be visualized as dark bands after coomassie
blue staining [13]. The strongest signals could be detected
for TIMP1. Densitometric quantification revealed a 4.9-
fold higher mean activity of TIMP1 in the good responder
group compared to poor responders. In contrast, detected
TIMP2 and TIMP3 activities were markedly lower and
showed a reverse distribution. Mean TIMP2 activity was
Fig. 2 Quantitative analysis of MMP2, MMP9, TIMP1, TIMP2 and TIMP3 gene and protein expression. a Real-time RT-qPCR analysis of MMP2, MMP9,
TIMP1, TIMP2 and TIMP3 gene expression in osteosarcoma biopsies from good and poor responders (n = 9 each). Expression levels were normalized
to the expression of RPL19 (ribosomal protein L19) in the corresponding sample. b Western blot analysis of MMP2, MMP9, TIMP1, TIMP2 and TIMP3
protein expression in osteosarcoma biopsies from good and poor responders (n = 9 each). Response to preoperative chemotherapy according to the
six-grade scale of Salzer-Kuntschik is indicated. c Densitometric quantification of the western blots shown in (b). The mean values ± SD of the analyzed
good and poor responder groups are shown
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4.7-fold higher in the poor responder group and mean
TIMP3 activity was elevated 6.6-fold compared to the
good responder group (Fig. 4a + b). In addition, we could
detect significant correlations between TIMP and MMP
activities. TIMP1 activity showed a positive correlation to
MMP9 activity (p = 0.012) and a negative correlation of to
MMP2 activity (p = 0.044). In contrast TIMP2 and TIMP3
activities were negatively correlated to MMP9 activity
(p = 0.007 and p = 0.006) and showed a positive correlation
to MMP2 activity (p = 0.022 and p = 0.000093) (Fig. 5).
Discussion
Numerous studies have demonstrated that MMPs play
critical roles in tumor growth and progression, the
development of metastases, angiogenesis and tumor
invasion [14–16] Elevated MMP levels have been associ-
ated with poor prognosis in several types of tumors in-
cluding breast cancer, gastric cancer and osteosarcoma
[17–21]. Among the more than 20 known members of the
MMP family, especially MMP2 and MMP9 have been ex-
tensively studied in human cancers and have been shown
to be closely related to the invasive potential and metasta-
sis of different types of tumor cells including osteosar-
coma [22, 23]. As a consequence, increased expression of
MMP2 and MMP9 have been associated with a more
aggressive phenotype and poor prognosis in several solid
tumors including breast cancer [24], ovarian carcinoma
[25], head and neck squamous cell carcinoma [26] and
gastric cancer [20]. However, the role of MMPs in osteosar-
coma and their value as prognostic marker is still unclear
Fig. 3 a Gelatine zymography of total protein lysates from osteosarcoma pretreatment biopsies. Latent pro- and active forms of MMP2 and
MMP9 were detected and are marked by arrows. Response to preoperative chemotherapy according to the six-grade scale of Salzer-Kuntschik is
indicated. (P = positive control, N = negative control) (b) Densitometric quantification of pro- and active forms as well as the total amount of
MMP2 and MMP9 in the good and poor responder group. The lower boundary of the box indicates the 25th percentile, and the upper boundary
the 75th percentile. The whiskers indicate the highest and lowest values. Medians are indicated. P-values were determined by Mann-Whitney
U-test (**p < 0.01, *p < 0.05). c Ratios of the active forms, the latent pro-forms and total MMP2/MMP9 in osteosarcoma biopsy samples
from good and poor responders. P-values were determined by Mann-Whitney U-test (**p < 0.01, *p < 0.05)
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and available data are conflicting. Most studies focused on
the involvement of MMPs in the metastatic process of
osteosarcomas based on their capacity to degrade ECM and
basement membranes, facilitating cellular motility and inva-
sion. In this context, upregulation of MMP9 but not
MMP2 has been shown to contribute to increased meta-
static ability of osteosarcoma cells [27]. Furthermore,
MMP9 activity and gene expression has been reported to
correlate with the metastatic potential of rat osteosarcoma,
while MMP2 could not be detected [28]. In stage IIB osteo-
sarcoma, the immunohistochemical status of MMP9 has
been shown to be strongly associated with overall and
disease-free survival [29]. However, a recent meta-analysis
including 18 studies covering 892 osteosarcoma patients
demonstrated that although MMP9 might be a potential
biomarker for osteosarcoma, a substantial heterogeneity ex-
ists among the different studies that could be attributed
mainly to methodical issues [30]. In contrast to MMP9, sev-
eral studies observed a more important role of MMP2 in
osteosarcoma. Analysis of MMP expression and activity in
osteosarcoma cell lines, biopsies and xenografts revealed a
strong expression of MMP2 in culture supernatants from
cell lines and in tumor xenografts while MMP9 expression
was below the detection limit. MMP inhibitors significantly
reduced the invasive potential of the analyzed cell lines
indicating a crucial role of MMP2 in this process [31].
Further, analysis of osteosarcoma cells isolated from 23
pretreatment tumor tissues showed high MMP2 levels
in all samples, while MMP9 could only be detected in
one sample [32].
Based on these contradictory results and our own ob-
servations we assumed that, in contrast to total RNA or
protein levels, the activity of these molecules in the
tumor tissue might be a more valuable parameter with
closer relation to their biological function. In fact, we
could detect significant differences of MMP and TIMP
activities between the analyzed good and poor responder
groups that could not be observed for total RNA and
protein levels. So far, the prognostic value of MMPs has
been evaluated mainly concerning overall and event-free
survival. Associations of MMPs with response to chemo-
therapy have not been studied yet. Current treatment
protocols include a risk adapted adjuvant therapy ac-
cording to the response to neoadjuvant chemotherapy
that can only be assessed after tumor resection. There-
fore, early stratification of osteosarcoma patients into
low and high risk groups in order to improve outcome
by means of a risk-adapted therapy is of high clinical
relevance. However, until today, no biomarker could be
established, allowing a risk stratification of osteosarcoma
patients at time of diagnosis- neither regarding the re-
sponse to current neoadjuvant chemotherapy protocols,
nor to overall survival. Interestingly, we identified a switch
from predominant MMP9 activity in the good responder
Fig. 4 a Reverse zymography of total protein lysates from osteosarcoma pretreatment biopsies. Equal amounts of protein were loaded on the
acrylamide gel supplemented with MMP2 and MMP9. TIMP mediated inhibition of MMP activity was detected as dark bands. Based on
their molecular weight TIMP1, TIMP2 and TIMP3 could be identified and are marked by arrows. (P = positive control, N = negative control)
(b) Densitometric quantification of TIMP1, TIMP2 and TIMP3. The lower boundary of the box indicates the 25th percentile, and the upper
boundary the 75th percentile. The whiskers indicate the highest and lowest values. Medians are indicated. P-values were determined by
Mann-Whitney U-test (**p < 0.01, *p < 0.05)
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group to predominant MMP2 activity in the poor re-
sponder group, suggesting that either loss of MMP9 activ-
ity or gain of MMP2 activity contributes to poor response
to chemotherapy. As possible explanation for the different
MMP activity patterns we identified diverse distributions
of MMP inhibitors in the analyzed groups. We observed
significant negative correlations of TIMP1 activity with
MMP2 activity as well as TIMP2 and TIMP3 activity with
MMP9 activity, suggesting that TIMP1 preferably inhibits
MMP2 while TIMP2 and TIMP3 mainly act on MMP9, at
least in the analyzed samples.
The observed association of MMP activity with response
to chemotherapy was unexpected and the mechanisms in-
volved are still unclear. Based on our previous results
demonstrating a significant association of low tumor
vascularization with good response to chemotherapy in
osteosarcoma patients [33] and the fact that MMPs are
crucially involved in the regulation of angiogenesis, we
suppose that altered neoangiogenesis links up MMP activ-
ity with response to chemotherapy. MMP2 and MMP9
have been shown to be crucial for the “angiogenic switch”
that occurs upon the initiation of tumor vascularization.
A reduction in tumor growth and vascularization has been
observed after transplantation of tumor cells into either
MMP2 [34] or MMP9 [35] deficient mice, compared to
wild-type mice. Further, expression of both, MMP2 and
MMP9 was upregulated in angiogenic islets during
carcinogenesis of pancreatic islets in transgenic mice.
However, MMP knock-out mice revealed MMP9 as a key
regulator of angiogenesis in this system, while MMP2 ra-
ther contributed to tumor growth [36]. In contrast,
MMP2 was identified as the prominent matrix metallo-
proteinase in the angiogenic nodules in a rat chondrosar-
coma model. Suppression of MMP2 activity by antisense
Fig. 5 Correlations of MMP and TIMP activities in osteosarcoma biopsies. MMP and TIMP activities were quantified by zymography, plotted
against each other and analyzed by Pearson Correlation. Correlation coefficients and p-values are indicated (**p < 0.01, *p < 0.05)
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oligonucleotides in the vascular nodules resulted in the
loss of angiogenic potential both in vitro and in vivo,
suggesting that MMP2 is required for the switch to
the angiogenic phenotype [37]. These and further
studies indicate that different MMPs are crucially in-
volved in tumor angiogenesis that in turn influences
response to chemotherapy.
To our knowledge, our study is the first showing a dir-
ect association of specific MMP activity patterns with re-
sponse to chemotherapy in osteosarcoma, indicating
that the ratio of MMP2 and MMP9 might be a valuable
prognostic marker in pretreatment biopsies to predict
the response to chemotherapy. We could further dem-
onstrate that zymography is a powerful tool to quantify
the activity of MMPs and TIMPs that might be closer
related to their biological functions compared to total
mRNA and protein levels. However, the small amount of
samples available for our analyses has to be considered
as limitation of our study. Quantification of MMP and
TIMP activities required high quality cryo conserved tis-
sue from osteosarcoma patients with known response to
chemotherapy and adequate size and quality for RNA
and protein extraction and further suitable for the pro-
duction of cryosections. In contrast to formalin fixed
paraffin embedded tissue such samples are much more
limited. Larger studies are needed to validate our find-
ings and to confirm the role of MMP2/MMP9 activity as
prognostic marker and possible target for therapeutic
interventions.
Conclusions
So far, data on the prognostic value of MMPs and their
inhibitors TIMPs in osteosarcoma are conflicting, most
likely due to different technical approaches. Applying
multiple zymography techniques we analyzed MMP and
TIMP activities and identified a shift from MMP9 to
predominant MMP2 activity in samples with poor re-
sponse to chemotherapy that could not be observed for
total mRNA or protein levels. Our preliminary data
demonstrate that the ratio of MMP2/MMP9 activity
might be a valuable prognostic marker for the response
to chemotherapy that can easily be analyzed by zymo-
graphy in tumor tissue samples. Our data further suggest
that MMPs represent a possible target for therapeutic
interventions.
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